## RDL Dank

Clean-up done; eyes now on road to recovery



BFSI - Banks > Result Update > April 26, 2025

CMP (Rs): 188 | TP (Rs): 225

RBL continued with its clean-up drive in Q4 as it fully provides for the MFI NPA portfolio leading to historically lower NNPA at 0.3%. However, the bank utilized its contingent provision buffer of Rs2.7bn which along with nearly flat margins and strong card fees helped manage profitability, albeit negligible at Rs0.7bn. Overall collection efficiency has improved in the MFI space, while SMA pool has reduced to Rs3.8bn/6.6% of the MFI book. RBL carries healthy provision on this SMA pool as well. Stress in the card portfolio too is easing, and the bank expects growth to recover gradually. The bank guides to better credit growth in FY26E, with heavy lifting to be done by the secured portfolio which may have some impact on margins. With CET 1 at 14.1% after the recent relaxation by the RBI on MFI risk-weights, RBL may not raise capital in a hurry. We retain BUY and our TP at Rs225, valuing the bank at 0.8x FY27E ABV. Further re-rating will be contingent on better visibility on its planned transformation toward the retail cum SME bank delivering sustained RoA/RoE of over 1%/10%.

### Guides to growth acceleration with focus on expanding the secured portfolio

Credit growth moderated to 10% YoY/2% QoQ due to planned slowdown in unsecured loans, particularly cards/MFI, as guided by the management. RBL also securitized the PL portfolio worth Rs4.5bn. Deposit growth too was soft, at 7% YoY/4% QoQ, while CASA ratio improved by 134bps QoQ to 34%, leading to lower CoD, aiding in sustaining margins at 4.9%. RBL continues to focus on growing its secured portfolio, incl retail and SME, by 25-30% in FY26; it will maintain MFI share at 6.5-7% of the overall book to support healthy RaRoC. The mgmt believes the cards portfolio has shown meaningful stabilization and shall thus pursue qualitative growth (mid-single digit) in this segment from Q2FY26.

### GNPA eases amid strong recoveries/write-offs despite elevated MFI stress

Gross slippages moderated QoQ, but remain elevated at Rs10.6bn/4.6% of loans (though lower than Rs13bn/5.8% in Q3), given higher stress in the MFI and card portfolios. However, higher recoveries/write-offs (especially in the wholesale segment), led to 32bps QoQ improvement in GNPA ratio to 2.6%, while higher PCR (incl accelerated provisions of Rs2.5bn in Q4 on the MFI portfolio to take MFI PCR to 100%) led to a decline in NNPA ratio to a historical low of 0.3%. The overall MFI SMA pool has reduced to Rs3.8bn/6.6% from Rs5.5bn/8%. The bank expects MFI and Card stress to ease in FY26, unless macros deteriorate meaningfully and thus expects credit cost to reduce, leading to better RoA.

### We retain BUY on RBL with unchanged TP of Rs225

We expect the bank's credit growth to be better in FY26E, while rate cut could provide tailwind to its margins, partly offset by portfolio shift toward the secured portfolio. This coupled with better asset quality/lower LLP should drive-up RoA, from 0.5% in FY25 to 0.8-1.2% over FY26-28E. We retain BUY with an unchanged TP to Rs225 (valuing at 0.8x FY27E ABV).

<b>RBL Bank: Financial</b>	Snapshot (S	Standalone)	)		
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Net profit	11,679	6,953	12,133	18,798	24,709
Loan growth (%)	19.6	10.3	14.4	16.2	18.2
NII growth (%)	20.9	7.0	6.5	16.0	18.8
NIM (%)	5.2	4.9	4.7	4.8	4.9
PPOP growth (%)	38.1	19.7	1.9	19.4	26.1
Adj. EPS (Rs)	19.4	11.5	20.0	30.9	40.6
Adj. EPS growth (%)	32.8	(40.9)	74.1	54.9	31.4
Adj. BV (INR)	237.9	254.0	268.9	294.6	329.0
Adj. BVPS growth (%)	9.8	6.7	5.9	9.6	11.7
RoA (%)	0.9	0.5	0.8	1.0	1.2
RoE (%)	8.2	4.6	7.5	10.7	12.7
P/E (x)	9.7	16.4	9.4	6.1	4.6
P/ABV (x)	0.8	0.7	0.7	0.6	0.6

Source: Company, Emkay Research

Target Price – 12M	Mar-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	19.7

Stock Data	RBK IN
52-week High (Rs)	272
52-week Low (Rs)	146
Shares outstanding (mn)	608.0
Market-cap (Rs bn)	114
Market-cap (USD mn)	1,338
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	10
ADTV-3M (Rs mn)	1,569.5
ADTV-3M (USD mn)	18.4
Free float (%)	97.7
Nifty-50	24,039.3
INR/USD	85.4
Shareholding,	
Promoters (%)	0.0
FPIs/MFs (%)	0.0/0.0

Price Performan	ice		
(%)	1M	3M	12M
Absolute	7.4	20.8	(28.5)
Rel. to Nifty	5.7	16.0	(32.8)



### **Anand Dama**

anand.dama@emkayglobal.com +91-22-66242480

### Nikhil Vaishnav

nikhil.vaishnav@emkayglobal.com +91-22-66242485

### Kunaal N

kunaal.n@emkayglobal.com +91-22-66121275

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded

# **Key Concall takeaways**

### **Outlook on loans**

### Credit growth to normalize gradually as asset quality stress, partner break-up are behind

- The portfolio has shown meaningful stabilization and is progressing toward normalization. Volatility in credit costs remains lower compared with the JLG segment, and the business remains profitable.
- The cards business is expected to grow at a mid-single-digit rate, with normalization anticipated from Q2. Acquisition filters are being enhanced amid an uncertain macro environment.

### ■ Microfinance stress to ease; the bank to increase CGFMU coverage

- The bank implemented MFIN Guardrail 2.0 in Q3FY25, ahead of peers. Disbursements in Q4 showed signs of recovery, aligning with the new risk framework.
- The bank is adopting a cautious stance in the JLG business. Currently, the bank is doing disbursement of Rs3.5bn/mth from Rs6-8bn/mth earlier, and expects disbursements to rise progressively in H2.
- **CGFMU coverage:** The bank covers eligible JLG disbursements under the CGFMU scheme by paying a 1% insurance premium on the portfolio. While compensation claims under this scheme typically take 18 to 24 months to process, the bank continues to actively file claims on NPAs as per eligibility. In the last two quarters, approximately 30% of disbursements were under CGFMU coverage, which significantly increased to 90% in Q4FY25. The bank is eligible to claim up to 15% of the covered portfolio annually.
- JLG is expected to be 6–7.5% of the overall portfolio.
- The bank expects 16–17% overall advance growth, with secured retail growing 25-30% and wholesale at 10-12% in FY26.
- Business loans originating from branches are currently at 33–35%, expected to increase to  $\sim$ 50% next year.
- CBG book composition includes 80% rated A and above.

### NIM set to dip, before it improves

- Deposit quality remains strong despite tighter liquidity and competition.
- NII: Impacted by lower disbursements in JLG and higher interest reversals.
- Margins may be flattish-to-low before moving upward, while the bank has levers to reduce the deposit rate that the bank can opt for.
- The bank has reduced SA and TD rates. While the cost benefits from these reductions will be realized with a lag, they are expected to exert pressure on margins in H1FY26. To mitigate this, the bank has taken steps to lower the SA rate, from 6.4% in Mar-25 to 5.6% by May-25.
- 45-47% of the portfolio is linked to EBLR/MCLR, while 45% is on fixed rates.

### Asset quality set to improve further; to lead to lower LLP

- The bank saw good improvement in early bucket collection efficiency and ended March at 99%, including Karnataka up from 98.4% as of Dec-24.
- The bank expects slippage to decline meaningfully in Q1 with a return to pre-stressed levels anticipated Q2FY26 onward.
- The bank saw continuous reduction of gross slippage in the cards and JLG segments. Gross slippages Credit Cards: Rs4.8bn vs Rs5.7bn QoQ; MFI: Rs4.7bn vs Rs5.4bn. Net slippages: JLG at Rs4.4bn vs Rs5.2bn; Cards: Rs4.4bn vs Rs5.3bn.

This report is intended for Team White Margue Solutions (team embay@whitemarguesolutions com) use and developed

- Overall Provisioning: a) The bank accelerated provisioning by adding Rs4.1bn over the policy requirement of Rs2.6bn, raising PCR to 85%. b) An additional Rs2.5bn was provided to fully cover GNPA in the segment. c) On the Rs3.8bn SMA book (as of Mar-25), the bank made 75% provisioning (~Rs2.8bn), utilizing existing contingent provisions.
- **Provisioning Policy:** The bank follows a conservative provisioning approach 70% on NPAs and 100% at 120 DPD in its card portfolio. The JLG segment now has 100% provisioning on NPAs as of Mar-25. The net NPA in the JLG book is nil.
- The bank's restructured book is stable at 0.29%.

### **Others**

- LCR stands at 133% as of Q4FY25. The bank expects a 3–4% positive impact expected from the recent LCR draft circulation.
- CET I ratio remains comfortable at 12.8–13%. Thus, the bank does not require capital in FY26.
- RoA is expected to trend upward, improving over FY25 levels.


# **Story in Charts**

Exhibit 1: Credit growth dipped further due to slowdown in unsecured loans and moderate corporate loan growth




Source: Company, Emkay Research

Exhibit 3: NIMs were flattish QoQ




Source: Company, Emkay Research

Exhibit 5: MFI stress persists in 4Q




Source: Company, Emkay Research

Exhibit 2: The bank remains focused on growing its secured loan portfolio




Source: Company, Emkay Research

Exhibit 4: Higher PCR led to historical lower NNPA at 0.3%




Source: Company, Emkay Research

Exhibit 6: The bank expects better growth, margin, and asset quality delivery to help improve RoA to 0.8-1.2% over FY26-28E



Source: Emkay Research

Exhibit 7: The stock currently trades at reasonable valuations



Source: Bloomberg, Emkay Research

**Exhibit 8: Actuals vs Estimates (Q4FY25)** 

(Damm)	Actuals	Estima	ates	Varia	tion	Comments	
(Rs mn)	Actuals	Emkay	Consensus	Emkay	Consensus		
Net income	25,631	24,972	25,981	3%	-1%	In-line NII and higher other income led to a beat	
PPOP	8,612	8,414	9,019	2%	-5%	Higher net income and contained opex led to a slight PPoP beat	
PAT	687	-1,223	475	NA	45%	PPOP beat, along with lower provisions, led to a PAT beat	

Source: Emkay Research

**Exhibit 9: Quarterly Summary** 

(Rs mn)	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	YoY (%)	QoQ (%)	FY24	FY25A	YoY (%)
Interest Earned	33,391	34,962	35,309	35,363	34,756	4	-2	123,943	140,391	13
Interest Expense	17,392	17,963	19,160	19,513	19,126	10	-2	63,514	75,761	19
Net Interest Income	15,999	17,000	16,150	15,851	15,630	-2	-1	60,429	64,630	7
Global NIMs (reported)	5.5	5.7	5.0	4.9	4.9	-56bps	-1bps	5.2	4.9	-27bps
Non-interest Income	8,755	8,055	9,274	10,733	10,000	14	-7	30,429	38,062	25
Operating Expenses	15,883	16,464	16,325	16,618	17,019	7	2	60,550	66,425	10
Pre Provisioning Profit	8,870	8,591	9,098	9,966	8,612	-3	-14	30,307	36,267	20
Provision & Contingencies	4,138	3,663	6,183	11,889	7,851	90	-34	17,785	29,586	66
PBT	4,732	4,928	2,915	-1,923	761	-84	-140	12,522	6,680	-47
Income Tax Expense (Gain)	1,206	1,213	690	-2,249	74	-94	NA	844	-273	-132
Net Profit/(Loss)	3,526	3,715	2,225	326	687	-81	111	11,679	6,953	-40
Gross NPA (%)	2.7	2.7	2.9	2.9	2.6	-5bps	-32bps	2.7	2.6	-5bps
Net NPA (%)	0.7	0.7	0.8	0.5	0.3	-45bps	-24bps	0.7	0.3	-45bps
Deposits (Rs bn)	1,035	1,014	1,080	1,068	1,109	7	4	1,035	1,109	7
Net Advances (Rs bn)	840	867	879	904	926	10	2	840	926	10

Source: Company, Emkay Research

**Exhibit 10: Revision in estimates** 

V/F Man (Danier)		FY26E			FY27E			FY28E	
Y/E Mar (Rs mn)	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	115,218	111,889	-2.9%	134,205	129,346	-3.6%	na	153,196	na
PPOP	42,043	36,950	-12.1%	50,772	44,135	-13.1%	na	55,657	na
PAT	12,169	12,133	-0.3%	19,684	18,798	-4.5%	na	24,709	na
EPS (Rs)	20.0	20.0	-0.3%	32.4	30.9	-4.5%	na	40.6	na
BV (Rs)	269.0	274.7	2.1%	298.4	302.6	1.4%	na	339.3	na

Source: Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded

**Exhibit 11: Key Assumptions** 

(%)	FY25A	FY26E	FY27E	FY28E
Loan Growth	10.3	14.4	16.2	18.2
Deposit Growth	7.2	15.1	17.2	19.0
NIM	4.9	4.7	4.8	4.9
GNPA	2.6	2.4	2.4	2.2
Credit Cost	3.5	2.0	1.5	1.5

Source: Emkay Research

**Exhibit 12: Key Ratios and Trends** 

	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Loans (Rs mn)	702,094	730,870	763,242	799,490	839,869	867,040	878,823	904,120	926,183
Loans YoY (%)	17.0	21.3	21.3	19.9	19.6	18.6	15.1	13.1	10.3
Loans QoQ (%)	5.3	4.1	4.4	4.7	5.1	3.2	1.4	2.9	2.4
Liability Profile (%)									
CASA	37.3	37.3	35.7	33.8	35.2	32.6	33.6	32.8	34.1
CA	17.4	17.7	16.5	15.0	17.4	14.6	15.3	13.8	16.2
SA	19.9	19.6	19.2	18.8	17.8	17.9	18.2	19.1	18.0
No. of Branches	517	520	528	538	545	545	550	558	561
NIM	5.6	5.5	5.5	5.5	5.5	5.7	5.0	4.9	4.9
Yield on Advances	12.60	12.80	14.03	14.00	14.12	14.20	13.54	13.30	13.00
Cost of Deposits	5.85	6.15	6.21	6.31	6.39	6.50	6.53	6.60	6.50
Asset Quality									
GNPA (%)	3.4	3.2	3.1	3.1	2.7	2.7	2.9	2.9	2.6
NNPA (%)	1.1	1.0	0.8	0.8	0.7	0.7	0.8	0.5	0.3
PCR (%)	68.1	69.6	75.6	75.1	72.7	73.1	73.0	82.2	89.0
Slippages (Rs mn)	6,810	5,550	5,410	6,660	6,800	7,200	10,260	13,090	10,580
Slippages - Annualized (%)	4.5	3.7	3.4	4.0	3.9	3.9	5.4	6.5	5.0
CAR (%)	17.0	16.7	16.5	15.7	16.2	15.2	15.9	15.4	15.5
Tier I (%)	15.3	15.1	15.2	14.6	14.4	13.8	14.2	13.7	14.1
ROE Decomposition on total assets (%)									
NII	4.8	4.9	4.9	4.9	4.8	5.0	4.6	4.5	4.3
Other Income (ex treasury)	2.3	2.2	2.2	2.3	2.5	2.2	2.4	2.7	2.5
Treasury	0.0	0.2	0.1	0.2	0.1	0.1	0.3	0.3	0.3
Opex	5.1	5.0	4.8	5.0	4.8	4.8	4.7	4.7	4.7
PPOP	2.1	2.2	2.4	2.4	2.7	2.5	2.6	2.8	2.4
Provisioning Cost	0.8	0.9	2.1	1.5	1.2	1.1	1.8	3.3	2.2
РВТ	1.3	1.3	0.3	1.0	1.4	1.4	0.8	(0.5)	0.2
Tax	0.3	0.3	(0.7)	0.2	0.4	0.4	0.2	(0.6)	0.0
ROA	1.0	1.0	1.0	0.7	1.1	1.1	0.6	0.1	0.2
ROE	8.1	8.4	8.4	6.5	9.7	9.9	5.8	0.8	1.8

Source: Company, Emkay Research

## **RBL Bank: Standalone Financials and Valuations**

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Interest Income	123,943	140,391	147,727	163,569	185,815
Interest Expense	63,514	75,761	78,913	83,735	91,007
Net interest income	60,429	64,630	68,815	79,833	94,808
NII growth (%)	20.9	7.0	6.5	16.0	18.8
Other income	30,429	38,062	43,074	49,513	58,388
Total Income	90,857	102,692	111,889	129,346	153,196
Operating expenses	60,550	66,425	74,938	85,211	97,539
PPOP	30,307	36,267	36,950	44,135	55,657
PPOP growth (%)	38.1	19.7	1.9	19.4	26.1
Core PPOP	28,952	32,563	33,061	40,440	52,147
Provisions & contingencies	17,785	29,586	20,832	19,060	22,636
PBT	12,522	6,680	16,119	25,075	33,020
Extraordinary items	-	-	-	-	-
Tax expense	844	(273)	3,986	6,277	8,311
Minority interest	0	0	0	0	C
Income from JV/Associates	-	-	-	-	
Reported PAT	11,679	6,953	12,133	18,798	24,709
PAT growth (%)	33.4	(40.5)	74.5	54.9	31.4
Adjusted PAT	11,679	6,953	12,133	18,798	24,709
Diluted EPS (Rs)	19.4	11.5	20.0	30.9	40.6
Diluted EPS growth (%)	32.8	(40.9)	74.1	54.9	31.4
DPS (Rs)	2.0	1.0	2.0	3.0	4.0
Dividend payout (%)	10.4	8.7	10.0	9.7	9.8
Effective tax rate (%)	6.7	(4.1)	24.7	25.0	25.2
Net interest margins (%)	5.2	4.9	4.7	4.8	4.9
Cost-income ratio (%)	66.6	64.7	67.0	65.9	63.7
Shares outstanding (mn)	605.1	607.9	607.9	607.9	607.9

Source: Company, Emkay Research

Asset quality and other	i illeti ics				
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Asset quality					
Gross NPLs	22,710	24,655	26,384	29,519	33,217
Net NPLs	6,200	2,708	4,749	6,494	8,304
GNPA ratio (%)	2.7	2.6	2.4	2.4	2.2
NNPA ratio (%)	0.7	0.3	0.4	0.5	0.6
Provision coverage (%)	72.7	89.0	82.0	78.0	75.0
Gross slippages	24,413	41,130	34,588	31,345	36,987
Gross slippage ratio (%)	2.9	4.3	3.2	2.5	2.5
LLP ratio (%)	2.1	3.5	2.0	1.5	1.5
NNPA to networth (%)	4.0	1.7	2.7	3.4	3.8
Capital adequacy					
Total CAR (%)	16.2	15.5	14.8	14.2	13.6
Tier-1 (%)	14.4	14.1	13.4	12.9	12.4
CET-1 (%)	14.4	14.1	13.4	12.9	12.4
RWA-to-Total Assets (%)	71.2	71.4	71.0	71.0	71.0
Miscellaneous					
Total income growth (%)	27.0	15.6	6.9	11.7	14.6
Opex growth (%)	14.6	9.7	12.8	13.7	14.5
Core PPOP growth (%)	39.7	12.5	1.5	22.3	28.9
PPOP margin (%)	19.6	20.3	19.4	20.7	22.8
PAT/PPOP (%)	38.5	19.2	32.8	42.6	44.4
LLP-to-Core PPOP (%)	61.4	90.9	63.0	47.1	43.4
Yield on advances (%)	13.1	12.8	12.0	11.7	11.4
Cost of funds (%)	5.9	6.3	5.9	5.5	5.1

Source: Company, Emkay Research

<b>Balance Sheet</b>					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	6,051	6,079	6,079	6,079	6,079
Reserves & surplus	141,913	149,989	160,906	177,880	200,158
Net worth	147,964	156,068	166,985	183,959	206,237
Deposits	1,034,936	1,109,435	1,277,509	1,497,534	1,781,754
Borrowings	141,841	137,338	141,065	149,018	157,319
Interest bearing liab.	1,176,777	1,246,774	1,418,574	1,646,553	1,939,073
Other liabilities & prov.	59,581	64,413	78,594	88,965	100,756
Total liabilities & equity	1,384,322	1,467,255	1,664,153	1,919,476	2,246,066
Net advances	839,869	926,183	1,059,233	1,230,782	1,454,579
Investments	295,759	321,648	364,912	423,067	495,568
Cash, other balances	144,166	125,596	134,765	148,190	164,821
Interest earning assets	1,279,793	1,373,426	1,558,910	1,802,039	2,114,968
					44 600
Fixed assets	5,324	5,771	8,010	9,760	11,639
Fixed assets Other assets	5,324 99,205	5,771 88,058	97,234	9,760 107,678	11,639
	•				119,459
Other assets	99,205	88,058	97,234	107,678	119,459
Other assets  Total assets	99,205 <b>1,384,322</b>	88,058 <b>1,467,255</b>	97,234 <b>1,664,153</b>	107,678 <b>1,919,476</b>	119,459 <b>2,246,066</b>
Other assets  Total assets  BVPS (Rs)	99,205 <b>1,384,322</b> 245.6	88,058 <b>1,467,255</b> 257.3	97,234 <b>1,664,153</b> 274.7	107,678 <b>1,919,476</b> 302.6	119,459 <b>2,246,066</b> 339.3
Other assets  Total assets  BVPS (Rs)  Adj. BVPS (INR)	99,205 <b>1,384,322</b> 245.6 237.9	88,058 <b>1,467,255</b> 257.3 254.0	97,234 <b>1,664,153</b> 274.7 268.9	107,678 <b>1,919,476</b> 302.6 294.6	119,459 <b>2,246,066</b> 339.3 329.0
Other assets  Total assets  BVPS (Rs)  Adj. BVPS (INR)  Gross advances	99,205 <b>1,384,322</b> 245.6 237.9 856,379	88,058 <b>1,467,255</b> 257.3 254.0 948,130	97,234 <b>1,664,153</b> 274.7 268.9 1,080,868	107,678 <b>1,919,476</b> 302.6 294.6 1,253,806	119,459 <b>2,246,066</b> 339.3 329.0 1,479,492
Other assets  Total assets  BVPS (Rs)  Adj. BVPS (INR)  Gross advances  Credit to deposit (%)	99,205 <b>1,384,322</b> 245.6 237.9 856,379 81.2	88,058  1,467,255  257.3  254.0  948,130  83.5	97,234 <b>1,664,153</b> 274.7 268.9 1,080,868 82.9	107,678  1,919,476  302.6 294.6  1,253,806  82.2	119,459 <b>2,246,066</b> 339.3 329.0 1,479,492 81.6
Other assets  Total assets  BVPS (Rs)  Adj. BVPS (INR)  Gross advances  Credit to deposit (%)  CASA ratio (%)	99,205 <b>1,384,322</b> 245.6 237.9 856,379 81.2 35.2	88,058 <b>1,467,255</b> 257.3 254.0 948,130 83.5 34.1	97,234 <b>1,664,153</b> 274.7 268.9 1,080,868 82.9 34.8	107,678 1,919,476 302.6 294.6 1,253,806 82.2 36.0	119,459 <b>2,246,066</b> 339.3 329.0 1,479,492 81.6 37.1
Other assets  Total assets  BVPS (Rs)  Adj. BVPS (INR)  Gross advances  Credit to deposit (%)  CASA ratio (%)  Cost of deposits (%)	99,205  1,384,322  245.6 237.9 856,379 81.2 35.2 5.7	88,058 1,467,255 257.3 254.0 948,130 83.5 34.1 6.1	97,234 <b>1,664,153</b> 274.7 268.9 1,080,868 82.9 34.8 5.8	107,678 1,919,476 302.6 294.6 1,253,806 82.2 36.0 5.4	119,459 <b>2,246,066</b> 339.3 329.0 1,479,492 81.6 37.1 5.1
Other assets  Total assets  BVPS (Rs)  Adj. BVPS (INR)  Gross advances  Credit to deposit (%)  CASA ratio (%)  Cost of deposits (%)  Loans-to-Assets (%)	99,205  1,384,322  245.6  237.9  856,379  81.2  35.2  5.7  60.7	88,058 1,467,255 257.3 254.0 948,130 83.5 34.1 6.1 63.1	97,234 1,664,153 274.7 268.9 1,080,868 82.9 34.8 5.8 63.6	107,678 1,919,476 302.6 294.6 1,253,806 82.2 36.0 5.4 64.1	119,459 2,246,066 339.3 329.0 1,479,492 81.6 37.1 5.1 64.8

Source: Company, Emkay Research

Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	9.7	16.4	9.4	6.1	4.6
P/B (x)	0.8	0.7	0.7	0.6	0.6
P/ABV (x)	0.8	0.7	0.7	0.6	0.6
P/PPOP (x)	3.8	3.2	3.1	2.6	2.1
Dividend yield (%)	1.1	0.5	1.1	1.6	2.1
DuPont-RoE split (%)					
NII/avg assets	4.8	4.5	4.4	4.5	4.6
Other income	2.4	2.7	2.8	2.8	2.8
Fee income	2.3	2.4	2.5	2.6	2.6
Opex	4.8	4.7	4.8	4.8	4.7
PPOP	2.4	2.5	2.4	2.5	2.7
Core PPOP	2.3	2.3	2.1	2.3	2.5
Provisions	1.4	2.1	1.3	1.1	1.1
Tax expense	0.1	0.0	0.3	0.4	0.4
RoA (%)	0.9	0.5	0.8	1.0	1.2
Leverage ratio (x)	9.0	9.4	9.7	10.2	10.7
RoE (%)	8.2	4.6	7.5	10.7	12.7
Quarterly data					
Rs mn, Y/E Mar	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25
NII	15,999	17,000	16,150	15,851	15,630
NIM (%)	5.5	5.7	5.0	4.9	4.9
PPOP	8,870	8,591	9,098	9,966	8,612
PAT	3,526	3,715	2,225	326	687
			3.7		

Source: Company, Emkay Research

### **ECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst	
09-Apr-25	169	225	Buy	Anand Dama	
19-Jan-25	155	225	Buy	Anand Dama	
01-Dec-24	155	250	Buy	Anand Dama	
20-Oct-24	205	325	Buy	Anand Dama	
07-Oct-24	190	325	Buy	Anand Dama	
21-Jul-24	240	350	Buy	Anand Dama	
28-Apr-24	265	350	Buy	Anand Dama	
21-Jan-24	269	350	Buy	Anand Dama	
21-Dec-23	276	350	Buy	Anand Dama	
30-Nov-23	235	320	Buy	Anand Dama	
26-Oct-23	216	320	Buy	Anand Dama	
22-Oct-23	244	320	Buy	Anand Dama	
23-Jul-23	222	275	Buy	Anand Dama	
23-May-23	147	225	Buy	Anand Dama	
01-May-23	162	225	Buy	Anand Dama	

Source: Company, Emkay Research

### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk D

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of April 26, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

### Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of April 26, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the April 26, 2025
- 5. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

	- <b>J</b>
Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded

### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.